Phase II Trial of Transdermal Estradiol in Patients With Hormone Refractory Prostate Cancer
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the antitumor activity, as measured by PSA response rate in patients with hormone and chemotherapy refractory prostate cancer.
4 years
Yes
Mark Stein, MD
Principal Investigator
University of Medicine and Dentistry New Jersey
United States: Food and Drug Administration
5247
NCT00176644
May 2005
October 2009
Name | Location |
---|---|
Morristown Memorial Hospital | Morristown, New Jersey 07962-1956 |
Cancer Institute of New Jersey | New Brunswick, New Jersey 08901 |
Overlook Hospital | Summit, New Jersey 07902-0220 |
Saint Peter's University Hospital | New Brunswick, New Jersey 08901-1780 |
Robert Wood Johnson University Hospital/CINJ at Hamilton | Hamilton, New Jersey 08690 |
CentraState Healthcare System | Freehold, New Jersey 07728 |